AUSTIN, Texas, Oct. 24 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX) today announced financial results for the third quarter ended September 30, 2007. Financial and operating highlights include the following:
-- Consolidated total revenue of $19.4 million, a 55 percent increase
year-over-year
-- System shipments again surpass 200 for the quarter, for an installed
base total in excess of 4,700, up 20 percent from a year ago
-- Consumables and royalty revenue up 64 and 22 percent, respectively,
from the prior year period. On a pro forma basis, adjusting for the
acquisition of Tm Bioscience, royalties grew by 35% over the third
quarter of 2006
-- Consolidated gross profit margin of 62 percent
-- Fifth Annual Planet xMAP Europe, the Company's European end-user
symposium in Amsterdam, attracted over 400 participants
Subsequent to the acquisition of Luminex Molecular Diagnostics (formerly Tm Bioscience) or LMD on March 1, 2007, Luminex has reported the results of the following segments in addition to the consolidated results: Technology Group and Assay Group. The Technology Group, which is our core business, consists of system sales to partners, raw bead sales, royalties, service and support of the technology and other miscellaneous items. The Assay Group consists of the Luminex Bioscience Group, or LBG, and LMD. This segment is primarily involved in the development and sale of assays on xMAP technology for use on the Company's installed base of systems.
Consolidated revenue for the third quarter of 2007 was $19.4 million, a
55 percent increase over third quarter 2006 revenues of $12.5 million. Net
loss for the thi
'/>"/>
| SOURCE Luminex Corporation Copyright©2007 PR Newswire. All rights reserved |